Post-stroke spasticity therapy options widen past oral baclofen
Botulinum toxin maturity, intrathecal baclofen pump access, and emerging novel mechanism programs are reshaping post-stroke spasticity management.
Post-stroke spasticity has been an oral antispastic and physical therapy category for years with botulinum toxin in selected populations. Botulinum toxin use is now well-established with multiple approved formulations and growing real-world data, intrathecal baclofen pump access is widening, and novel mechanism programs (myostatin pathway, alpha-adrenergic, others) are in late-stage trials. The infrastructure question (specialist injection capacity, integrated rehabilitation services) bounds the addressable population.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- SnapshotAcute ischemic stroke therapy reference (2026)
- ExplainedWhat is spasticity?